Overall survival according to cytogenetic risk category. The 3 sets of curves illustrate the overall survival of patients randomized to combination chemotherapy with or without GO. (A) Overall survival of 246 patients with favorable-risk AML. (B) Overall survival of 1827 patients with intermediate-risk AML. (C) Overall survival of 583 with adverse-risk disease.²⁴  SD, standard deviation.